scholarly journals Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study

2017 ◽  
Vol 49 (6) ◽  
pp. 692-696 ◽  
Author(s):  
Juliette Viaud ◽  
Clémence Brac ◽  
Pascal Artru ◽  
Estelle Le Pabic ◽  
Bérengère Leconte ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Pancreatic Adenocarcinoma ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Advanced Pancreatic Adenocarcinoma ◽  
Line Chemotherapy

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Oncology ◽  
2011 ◽  
Vol 80 (5-6) ◽  
pp. 301-306 ◽  
Author(s):  
Elias Assaf ◽  
Muriel Verlinde-Carvalho ◽  
Catherine Delbaldo ◽  
Julien Grenier ◽  
Zineb Sellam ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Metastatic Pancreatic Adenocarcinoma ◽  
Line Chemotherapy

Impact of nab-paclitaxel-based second-line chemotherapy on the outcomes of pancreatic cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 483-483
Author(s):  
Neelakanta Dadi ◽  
Safi Shahda ◽  
Bert H. O'Neil ◽  
Amikar Sehdev
Keyword(s):  
Retrospective Study ◽  
Performance Status ◽  
Locally Advanced ◽  
Group Versus ◽  
Ductal Adenocarcinoma ◽  
Cancer Center ◽  
Line Treatment ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

483 Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with no standard second line chemotherapies. We conducted a retrospective study with the primary aim to examine the effect of second line chemotherapy with nab-paclitaxel-based regimen on the overall survival (OS) and progression-free survival (PFS) of locally advanced and metastatic PDAC patients. Methods: Indiana University Simon Cancer Center (IUSCC) Cancer Registry was used to identify patients with locally advanced or metastatic PDAC between 2009 and 2015. Only patients who received second line chemotherapies were included in the study. These patients were divided in to two groups: a) nab-paclitaxel-based treatment and, b) non-nab-paclitaxel-based treatment. Demographic (age, race, gender, year of diagnosis, family history, comorbidity), clinical (histology, CA 19-9, bilirubin, tumor location, performance status, metastatic sites, chemotherapy, surgery or radiation) and outcome (OS, PFS) characteristics were obtained. OS and PFS were estimate by using Kaplan-Meier method and 95% CI. Cox proportional-hazard model was used for multivariate analysis. Results: Forty-seven (39%) and seventy-three (61%) patients received nab-paclitaxel-based and non-nab-paclitaxel-based second line chemotherapy, respectively. In the univariate analyses, nab-paclitaxel-based treatment was only associated with younger age (60.4 vs. 64 years; P = 0.02). The median PFS was 2.8 and 2.1 months (HR 0.62; 95% CI 0.38-1.02; P = 0.06), and the median OS was 7.5 and 4.7 months (HR 0.67; 95% CI 0.45-1.00; P = 0.05) in patients who received nab-paclitaxel based second line treatment versus not, respectively. Multivariate analyses adjusted for age showed a significantly improved PFS (adjusted HR 0.60, 95% CI 0.36-0.98; P = 0.04) and a suggestion of improved OS (adjusted HR 0.67; 95% CI 0.44-1.01, P = 0.05) in the nab-paclitaxel based second line treatment group versus not, respectively. Conclusions: In a single institution retrospective study, we report significant improvement in the PFS and a suggestion of improvement in the OS with nab-paclitaxel based treatment as compared with non-nab-paclitaxel based treatment in the second line setting.

Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India

2018 ◽  
Vol 55 (2) ◽  
pp. 144
Author(s):  
Vikas Ostwal ◽  
Anant Ramaswamy ◽  
Sangeetha Parthiban ◽  
Mridul Malhotra ◽  
Rushabh Kothari ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Cancer Center ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Pancreatic Cancers ◽  
Tertiary Cancer Center ◽  
Line Chemotherapy

scholarly journals Expanded analysis of mFOLFIRINOX as second-line chemotherapy in pancreatic adenocarcinoma

2017 ◽  
Vol 28 ◽  
pp. iii75
Author(s):  
Andrew Dean ◽  
Domenic Higgs ◽  
Alex James ◽  
Tegan Van Gemert ◽  
Alena James
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

The Retrospective Study of Second-line Chemotherapy in Ovarian Cancer

2003 ◽  
Vol 29 (1) ◽  
pp. 56-56
Author(s):  
Hiroshi Nishii ◽  
Makoto Yasuda ◽  
Toshiki Wachi ◽  
Eizo Kimura ◽  
Kazuhiko Ochiai ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Retrospective Study ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document